GlaxoSmithKline is selling its anesthetic medicine portfolio to Aspen Pharmacare in a deal worth as much as $372 million.

GSK had already sold the drugs involved in U.S. and Canadian markets.

The deal was announced early Monday.

The drug rights sold include Ultiva, Nimbex, Tracrium, Mivacron and Anectine, according to GSK.

The deal includes an initial payment and and furhter payments based on hitting certain benchmarks.

Aspen, which is based in South Africa, in June bought a number of anesthetic drugs from AstraZeneca for some $770 million, according to Bloomberg news.

GSK (NYSE: GSK) maintains a major presence in the RTP areas for research and development as well as product production.

Read more at: